rFXIII (NN8717)

:Inflammation - Ulcerative colitis
:Phase 2

A recombinant coagulation factor XIII investigating the biological and clinical effect on mucosal healing in patients with mild to moderate active ulcerative colitis. Approved for congenital FXIII deficiency in the EU, Canada and Switzerland.

Company announcements
No company announcements matching the search criteria
 

Press releases
No press releases matching the search criteria
 

Scientific abstracts

No scientific abstracts matching the search criteria


You can search for more clinical trials on http://clinicaltrials.gov
  •